Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) today reported positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The results validate the company's core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases.
The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance, successfully achieving the primary objectives required to progress the clinical program. Patients with severe visual impairment, some with uncorrected preoperative acuities as poor as 20/250—levels consistent with legal blindness—experienced meaningful improvements in everyday vision.
“These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes,” said Dean Burns, President and CEO of Ocumetics. “Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100% confident in our accommodating intraocular lens technology. Based on this success, we have initiated planning for Group 2 surgeries.”
Dr. Rafael Vázquez, principal investigator of the Ocumetics first-in-human trial, highlighted the life-changing impact on patients: “All patient outcomes have met safety expectations. The profile of the patients I selected had poor vision, and as a result of the implantations, they have experienced truly a life changing event. From being classified legally blind, my patients can now read, enjoy everyday life activities, and drive. The impact on their independence and sense of freedom has been remarkable.”
The results from Group 1 can be summarized as: safety profile met expectations, visual acuity outcomes met and exceeded expectations, and lens delivery system met expectations.
Ocumetics continues to apply its rapid “win-learn” R&D approach, incorporating surgeon feedback in real time to further optimize performance. Based on insights from Group 1, the company has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in Group 2. Manufacturing and testing of optimized lens designs are currently underway, with Group 2 surgeries expected to be scheduled following completion of final lens testing and validation.
“Our Group 1 results clearly demonstrated and confirmed the viability of our accommodating intraocular lens technology,” concluded Burns. “This milestone materially strengthens our clinical foundation and positions Ocumetics to build momentum as we advance into Group 2. We are excited to continue executing on our clinical and development roadmap.”
Ocumetics will host a webinar on February 4, 2026, at 4:00 PM ET to discuss the results and updates on the FIH study. More details are available at www.ocumetics.com/webinar.
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company's accommodating intraocular lens is designed to allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. This announcement underscores the significant progress made in bringing this technology to patients.
